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Abstract The goal of the present work is to give a
review of developments achieved experimentally in the
field of nuclear data for medically important radioiso-
topes in the last three years. The availability and preci-
sion of production related nuclear data is continuously
improved mainly experimentally. This review empha-
sizes a couple of larger fields: the Mo/Tc generator
problem and the generator isotopes in general, heavy
alpha-emitters and the rare-earth elements. Other re-
sults in the field of medical radioisotope production are
also listed.
Keywords: charged particle induced nuclear reac-
tions; medical radio-isotopes; review
1 Introduction
Nuclear data play an important role in the production
and the application of medical radioisotopes. Out of
the basic nuclear data, the activation cross sections and
the related production yields are also requested. These
data can be obtained experimentally and/or by using
nuclear reaction codes. The significance of the experi-
mental data is twofold: they give direct information for
the production and they also contribute to the develop-
ment of nuclear reaction model codes. During the previ-
ous dedicated and satellite investigations, large amount
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of activation data were measured. In spite of the large
experimental databases and the significant progress in
the reaction theory, the importance of collection of re-
liable experimental data has not decreased. New can-
didate radioisotopes appear for diagnostics and ther-
apy, the radioisotope impurities became more impor-
tant, new experimental techniques appear to measure
low radio-activities, weak performance of nuclear theory
was recognized for some type of nuclear reactions and
for the metastable states, preparation of recommended
databases require re-measurement of mostly used reac-
tions due to contradicting data. Application of high-
energy accelerators, usefulness of deuteron induced re-
actions, broader application of numerous low energy
cyclotrons all require further data measurements and
improvements. Nuclear data for medical applications
are mainly used in the following fields: production of
radioisotopes (medical), dosimetry calculations (staff,
patients), radiotherapy planning, diagnostics and econ-
omy (planning of the production, distribution, treat-
ment, etc.). The necessary nuclear data can be divided
into two larger groups: i.e. structure and decay data,
which are mainly interesting for fundamental research
but also used for medical physics, and the excitation
functions and production yields, which are rather appli-
cation related data. The sources of stored nuclear data
are manifold, if one is interested in the source publica-
tions, then turns to such publication databases as the
WoS (Web of Science) [1]. If more precise compiled data
are necessary then the source is the EXFOR (Experi-
mental Nuclear Reaction Data) [2] database, and eval-
uated data can be found in the newest version of the
ENDF (Evaluated Nuclear Data Library) [3] libraries.
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2 Experimental data
The most important medically related radioisotopes and
their basic nuclear data are listed in different literature
sources [4,5,6,7,8,9,10,11,12,13,14] and summarized
in Table 1. These sources might not contain the new
emerging radioisotopes under investigation, which are
referred in the following sections. If really reliable pro-
duction related data are needed, one can search in the
experimental databases. The experimental groups per-
form their measurements by using: activation method,
sometimes followed by chemical separation, on solid or
gas targets. Single target, rotating wheel or stacked tar-
gets are used. The activity is measured by using γ-,
X-ray and α-spectrometry or mass spectrometry. The
most frequent goals of these studies are: new isotopes
for medical, industrial and other purposes; new produc-
tion routes of important isotopes; side reactions and
impurities; clarification of disagreements between pre-
vious measurements. According to our experiences, the
published results are not always free of problems. These
problems can be summarized as follows:
– The available poor technology in some laboratories
(beam intensity, beam energy measurement, target
preparation, chemical separation)
– Missing basic knowledge on data measurement, data
evaluation, definitions, etc.
– Too optimistic uncertainties
– The reports are not detailed enough for data correc-
tions and for production of covariance matrices
Some groups, especially those participating in coordi-
nated research programs try to address these problems
in the recent publications. In addition, people responsi-
ble for database inputs pay more attention to the above
problems when evaluating a new work. Out of medi-
cal applications, the published results can also be used
for basic nuclear physics research, development of the-
oretical models, improvement of computer codes based
on these models, industrial applications, energy related
and safety/security related applications. According to
the last IAEA recommendations [4] particular data im-
provements are needed at the following areas:
– Monitor reactions (induced by light ions in the used
energy ranges)
– Diagnostic and therapeutic γ-emitters (123,121I, 123Cs,
123Xe, 51Cr, 186,188Re, 99m,gTc, 90m,gY, 99Mo)
– Positron emitters (52Fe, 55Co, 61Cu, 66,68Ga, 90Nb,
89Zr, 73Se, 76Br, 86Y, 89Zr, 94mTc, 110mIn, 120I)
– Generators (62Zn/62Cu, 68Ge/68Ga, 72Se/72As,
82Sr/82Rb)
– Therapeutic α-emitters (225Ra, 225,227Ac, 230U, 227Th)
– Therapeutic electron and X-ray emitters (131Cs, 178Ta)
Out of these recommendations also the 111In, 201Tl,
119Sb, 97Ru therapeutic electron and X-ray emitters re-
quire further data improvements. The recently emerged
theranostic approach in nuclear medicine, which con-
sists of performing imaging of the bio-distribution and
therapy in the same time, by using the same isotope
or different isotopes of the same element or isotopes of
two elements with similar chemical behavior, opened a
new field in nuclear data experiments and renewed the
interest for some radionuclides. In the last 3-4 years,
developments have been achieved in the field of exper-
imental production data in the following four areas.
2.1 Production of 99Mo/99mTc generator
Shutdown and decommissioning of several nuclear reac-
tors responsible for the large-scale production of 99Mo
caused (or will cause in the near future) a shortage on
the market of the 99Mo/99mTc generator system. Sev-
eral attempts have been made to elaborate methods to
substitute the reactor HEU (highly enriched uranium)
production route by LEU (low enriched uranium tar-
get), fast neutron [15,16], high energy photon [17] and
charged particle irradiation, both for 99Mo production
[18,19] and direct 99mTc production [20]. Fig. 1 shows
results on charged particle production routes for pro-
ton, deuteron and α-particle induced reactions on natu-
ral and enriched molybdenum targets. From Fig. 1, one
can see that if there are more than one published exper-
imental datasets for a reaction type (e.g. (d,x) reaction
by Chodash [18] and Ta´rka´nyi [6]) ), the agreement be-
tween the independent experiments is very good. If the
results on enriched targets are normalized to be com-
pared with natural targets, the agreement is also good
except for the lower energy part of the measured exci-
tation functions. Fig. 1 also shows that the alternative
production route of 99Mo can be the deuteron activa-
tion, but the availability of higher energy deuterons (Ed
15 MeV), by the commercial medical accelerators, is
limited. Moreover, deuterons have a shorter range in
matter than protons, which gives a lower thick target
yield for equivalent cross section values, thats why the
proton production route is also competitive [21].
2.2 Heavy α-emitters
α-emitter isotopes have a promising future in the field
of targeted radio-therapy. The emitted α-particles are
relatively heavy projectiles, having different energies
with short range in human tissues. Thats why they
can easily induce the medically required double-strand
DNA break in the tumor cells without damaging the
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Fig. 1 Recent results on 99Mo production by charged parti-
cle activation on natural Mo [6,7,18,19] and 100Mo enriched
targets [20]
surrounding healthy cells. New results have been pub-
lished for the α-particle and proton induced production
of 211At [22] and 225Ac [23,24] respectively. The ac-
tinide radioisotope 225Ac has a half-life of 10 days, emits
four alpha particles in its decay chain, and has recently
gained importance for application in future treatment
of metastatic cancer via targeted α-immunotherapy [25].
225Ac can also be used as a generator for 213Bi, another
shorter-lived α-emitter (T1/2 = 45.6 min) considered for
targeted alpha therapy. Up till now, the widespread use
of 225Ac and 213Bi in radiotherapy has been restricted
by the limited availability of 225Ac. Presently, 225Ac is
almost exclusively supplied by separating the isotope
radio-chemically from only two 229Th sources, one lo-
cated at Oak Ridge National Laboratory (ORNL), USA
[26] and the other at the Institute for Transuranium El-
ements in Karlsruhe (ITU), Germany [27]. The 229Th,
available at both sites was recovered from 233U, which
was in long-term storage at ORNL. This 233U was pro-
duced in kilogram quantities in the 1960s by neutron
irradiation of 232Th in molten salt breeder reactors [28].
Another radionuclide of interest, 223Ra, has a half-life of
11.4 days and also emits four alpha particles in its decay
chain. It is a promising candidate for the treatment of
bone cancer [29]. It can also be used as a generator for
the production of 211Pb [30]. Proton induced produc-
tion of more than 80 isotopes on thorium was measured
at high and low proton energies [31,32]. New results on
production of 223Ra, 225Ac [24] and 227Th [23,24] were
published recently. As an example, in Fig. 2, recent re-
sults (2012) for proton-induced reaction cross section
of 225Ac on a thorium target are shown. Two groups
measured this excitation function in overlapping energy
ranges. The agreement in the medium energy region is
not so good.
Fig. 2 New results on the production of 225Ac by high en-
ergy proton irradiation of 232Th
2.3 Rare earth elements
As there are a lot of emerging medical radioisotopes be-
tween the rare earth elements, most of the new results
have been published in this field. Out of the rare earth
radioisotopes, also new data for other important radio-
products (side products) were determined. New experi-
mental data were published for proton induced produc-
tion of Hf, Lu and Ta radioisotopes on natural Hf target
[33], proton induced production of Ho radioisotopes on
Dy target [34], Zr, Y, Sr, Rb radioisotope production
on natural yttrium by proton irradiation [35], measure-
ment of the excitation functions of Pm, Nd, Pr and Ce
radioisotopes on natural Nd target with deuteron acti-
vation [36], production of Yb and Tm radioisotopes on
thulium target by proton activation [37]. As an exam-
ple, the new production cross section of the medically
interesting therapeutic 161Ho radio-lanthanide, which is
an Auger-electron emitter, is presented in Fig. 3. This
cross section has not been measured before, thats why
the results were compared with the output of the dif-
ferent theoretical nuclear reaction model codes (such as
TALYS, ALICE and EMPIRE [38,39,40]). These codes
give good trend but different and incorrect quantitative
estimation for the cross section.
2.4 Generators
Radioisotope generators are very important in the ev-
eryday medical practice, because they make possible
the access to short-lived radioisotopes without the pres-
ence of a medical accelerator in the vicinity of the hos-
pital. The most important generator/daughter pair is
the 99Mo/99mTc, which was discussed in detail in a
previous section. As an example for this part, the new
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Fig. 3 Excitation function of the medically important 161Ho
radioisotope by proton bombardment of natural dysprosium
and comparison with the results of the different nuclear reac-
tion model codes
Fig. 4 Latest results on production cross sections for 62Zn
with proton (Jost, Khandaker, Siiskonen, Uddin [32,41,42,
43]) and deuteron (Simeckova [44]) irradiation of copper tar-
gets
results on 62Zn for 62Cu generator is shown in Fig. 4.
It contains both proton [32,41,42,43] and deuteron [44]
induced routes. From the results presented in Fig. 4,
only the data of Jost [32] for proton irradiation and the
data of Simeckova [44] for deuteron irradiation are new
(from the last three years), the others are presented for
comparison. The figure shows that the newest 62Zn data
for proton irradiation support the previous results and
also confirm that the proton induced route is preferable
than the deuteron one for its production. New results
have also been published for 178W production (gener-
ator for 178Ta) [45,46], for 44Ti production (generator
for 44Sc) [47], for 140Nd (generator for 140Pr) [48] and
for 149Pm (generator of 149Nd) [36].
2.5 Other new results
New results on other medically interesting nuclear data
have also been published in the last three years:
– Production cross section of 110m,110g,111g,114mIn on
natural cadmium with α-particle irradiation and many
side reactions producing In, Cd and Sn radioisotopes
[49] (PET, electron emitter respectively).
– Production cross section of 186gRe with deuteron
[50] and proton [45] irradiation on natural tungsten
target and side products (therapy).
– Production cross section of 203,201Pb and 201Tl on
natural thallium with proton irradiation and many
side products [51] (SPECT).
– Production parameters of 105Rh by proton irradia-
tion of natural palladium [52] (therapy).
– Production cross section of 167Tm and many side
thulium and ytterbium products by proton irradia-
tion of natural thulium [37] (therapy).
– Production cross section of 66,67,68Ga by proton ir-
radiation of 68Zn and α-particle irradiation of nat-
ural copper [53] (SPECT, PET).
– Production cross section of 90,95gNb and 88Y with
side products by proton irradiation of natural zirco-
nium [54] (PET).
– Production cross section of 11C, 15O and 13N iso-
topes by proton irradiation of the corresponding tar-
get elements [55] (PET).
– Production of 67Cu by deuteron irradiation of nat-
ural zinc [56] (therapy).
– Production cross section 123Cs by proton irradiation
of 124Xe [57] (SPECT).
– Production cross section of 123Xe by α-particle [58]
and proton irradiation of 120Te and 124Xe targets
[57] respectively (SPECT).
– Production cross section of 51Cr by proton irradia-
tion of natural chromium, 56Fe [59], natural nickel,
93Nb [60], 55Mn [61] and 59Co [62] as well as by
deuteron irradiation of natural iron [63,64], natu-
ral vanadium [65], 55Mn [66], natural chromium [67]
and natural nickel [68,69], production of 52Mn by
proton irradiation of natural chromium [70] (SPECT,
PET).
– Production cross section of 90Nb by proton induced
reactions of natural zirconium [54], 93Nb [60,5] and
natural molybdenum [19], deuteron [6] and α-particle
[7] induced reaction on natural molybdenum (PET).
– Production cross sections of 147,149Gd by proton and
deuteron induced reactions on natural europium [71]
(SPECT).
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3 Conclusions
The status of the nuclear reaction databases for medical
applications has been significantly improved. Further
developments are important in both the reaction and
decay fields. It requires new, dedicated experiments,
reliable (proved) experimental technique, new evalu-
ation technique and proper reporting of the experi-
mental data. Some isotopes are emerging, especially
in the field of theranostic applications. It requires fur-
ther measurements for these new isotopes and also re-
measurements of isotopes having renewed interest. The
results provided by the nuclear reaction model codes
are not always satisfactory, thats why further and closer
co-operation is necessary between the code developers
and experimental groups. The huge amount of new data
on medical radioisotopes confirms the large potential
of experimental groups behind the work. The IAEA
NDS is only one organization trying to promote and
improve the co-operation in the nuclear data, especially
the medical nuclear data field. Independent groups also
provided important contribution to the experimental
nuclear data for the medical radioisotopes (see in the
section Other new results).
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Table 1 List of important and emerging medically interesting radioisotopes, for which charged particle pro-
duction route exist and/or measured recently [1,2,3,4] (new measurements marked with *)
Radionuclide Half-life Decay mode Reaction (main routes) Application
11C* 20.4 min β+ (100%) 14N(p,α)11C Positron emitter
13N 10 min β+ (100%) 16O(p,α); 12C(d,n) Radiotracer, PET, labelling
15O* 2.03 min EC (0.1%); β+ (99.9%) 15N(p,n); 14N(d,n); 16O(p,pn); 12C(α,n) Labelling, flow measurement
18F* 109.8 min EC (3%); β+ (97%) 18O(p,n); natNe(d,x)18F PET
22Na* 2.6 a EC (9.6%); β+ (90.6%) 22Ne(p,n); 22Ne(d,2n), 24Mg(d,α) PET calibration
34mCl 32 min IT (44.6%); β+ (54.3%) natCl(p,pxn); 34S(p,n); 34S(d,2n) PET
38K* 7.636 min EC (0.47%); β+ (99.53%) 35Cl(α,n), 38Ar(p,n) PET
43K* 22.3 h β− 100 % 40Ar(α,p)43K biology
44Sc
44Ti/44Sc*
3.97 h
59.1 a/ 3.97h
EC (5.73%); β+ (94.27%)
ε (100%)
44Ca(p,n)44Sc; 44Ca(d,2n)44Sc;
45Sc(p,2n)44Ti; 45Sc(d,3n)44Ti
PET
51Cr* 27.701 d ε (100%) natV(p,n);natV(d,2n);natTi(α,x) in vitro assay
γ-emitter
52mMn
52Fe/52mMn*
21.1 min
8.275 h
EC (3.25%); β+ (95.0%);
IT (1.75%)
ε: (100%)
55Mn(p,4n)52Fe; natNi(p,x)52Fe;
52Cr(3He,3n)52Fe
PET
55Co* 17.6 h EC (23%); β+ (77%) 56Fe(p,2n); 54Fe(d,n); 58Ni(p,α), natFe(p,x) PET
61Cu* 3.333 h EC (39%); β+ (61%) 61Ni(p,n); natNi(d,x) PET
62Cu
62Zn/62Cu*
9.67 min
9.193 h/ 9.67 min
EC (2.17%); β+ (97.83 %)
ε (100%)
63Cu(p,2n)62Zn; 63Cu(d,3n)62Zn;
60Ni(α,2n)
PET
64Cu* 12.7 h EC (44%); β+(17%); β− (39%) 64Ni(p,n);64Ni(d,2n); 68Zn(p,αn); 66Zn(d,α) PET, therapy, Cu metabolism
67Cu* 62 h β− (100%) 64Ni(α,p); 68Zn(p,2p); 70Zn(p,α) Therapy
63Zn 38 min EC (7%); β+ (93%) 63Cu(p,n) PET biomarker for Zn
66Ga* 9.49 h EC (43%); β+ (57 %) 66Zn(p,n); 63Cu(α,n) PET
67Ga* 3.26 d EC (100%) 67Zn(p,n); 68Zn(p,2n) SPECT
68Ga*
68Ge/68Ga*
68 min
270.8 d/68 min
EC (11%); β+ (89%)
ε (100%)
68Zn(p,n)
natZn(α,x); natGa(p,x); 69Ga(p,2n)
PET imaging, PET calibration
72As*
72Se/72As
26.0 h
8.40 d/26.0 h
EC (12.2%); β+ (87.8%)
E (100%)
natGe(p,xn)72As
75As(p,4n)72Se; natBr(p,x)72Se
PET
73As* 8.3 d ε (100%) natGe(p;α,x) PET and labelling
74As* 17.8 d ε (100%) 74Ge(d;p,xn); natGa(α,x) PET (cancer diagnostics)
73Se* 39.8 min EC (79.6%); β+ (20.4%) 75As(p,3n), 72Ge(α,3n) PET
75Br* 97 min β+ (75%) EC (25%) 7xSe(p;d;3He;α,X); 78Kr(p,α) PET
76Br* 16.2 h β+ (54%) EC (46%) 76Se(p,n); 77Se(p,2n); 75As(α,3n),
natSe(p,xn); natBr(p,xn); natBr(d,xn),
78Kr(d,α)
PET
77Br 57 h EC (99.3%) β+(0.73 %) natSe(p,xn); 75As(α,2n) SPECT, therapy
81mKr
81Rb/81mKr*
13 s
4.6 h/13 s
IT (99.9975%) 81Rb daughter
82Kr(p,2n); 80Kr(d,n)
Pulmonology, SPECT
82Rb
82Sr/82Rb*
1.3 min
25 d/1.3 min
EC (4.57%); β+ (95.43%)
ε (100%)
82Sr daughter
85Rb(p,4n); natRb(p,xn); 82Kr(α,4n),
82Kr(3He,3n)
PET
86Y* 14.7 h EC (66%); β+ (34%) 86Sr(p,n); 88Sr(p,3n); natZr(d,x) Tracing of 90Y bone pain palliation
agent
90Nb* 14.60 h EC (48.8%); β+ (51.2%) 90Zr(p,n); 90Zr(d,2n) PET
88Y
88Zr/88Y*
106 d
83.4 d/106 d
ε (100%)
ε (100%)
88Sr(p,n)88Y; natRb(α,xn)88Y
89Y(p,2n); 89Y(d,3n)
Tracing of 90Y
89Zr* 3.3 d EC (77%); β+ (23%) 89Y(p,n); 89Y(d,2n) PET, labelling
94mTc 52 min EC (28%); β+ (72%) natMo(p,n); natMo(α,x) also on enriched
targets
PET imaging, 99mTc replacement
99mTc*
99Mo/99mTc*
6.0067 h
65.976 /6.0067 h
IT (99.9963%); β− (0.0037%)
β− (100%)
100Mo(p,2n)99mTc;100Mo(d,3n)99mTc
100Mo(p,pn)99Mo; 100Mo(d,p2n)99Mo
SPECT
103Pd* 17 d ε (100%) 103Rh(p,n); 103Rh (d,2n) Brachytherapy
111Ag* 7.45 d β− (100%) 110Pd(d,n) Therapy
109Cd* 461.4 d EC (100%) 109Ag(p,n); 107Ag(α,x) 109Cd/109mAg biomedical genera-
tor
110mIn*
110Sn/110mIn*
69 min
4.9 h/69 min
EC (99%); β+ (0.008%)
ε (100%)
110Cd(p,n); 110Cd(d,2n)
natIn(p,x); natCd(3He,x); natCd(α,x)
PET analogue of 111In; labelling
111In* 2.83 d EC (100%) 111Cd(p,n); 112Cd(p,2n); 109Ag(α,2n) SPECT, diagnostics
113mIn*
113Sn/113mIn*
99.476 min
115.09 d
IT (100%)
EC (100%)
natCd(p,x);114Cd(p,2n);natCd(d,x)113mIn;
114Cd(d,3n)113mIn
natCd(3He,xn)113Sn; natSn(p,x)113Sn;
natSn(d,x)113Sn; natCd(α,xn)113Sn;
113In(p,x)113Sn; natIn(p,x)113Sn;
113In(d,x)113Sn;natIn(d,x)113Sn;
111Cd(α,x)113Sn
SPECT, radio-tracer, therapy
114mIn* 49.5 d IT (96.75%); e (3.25%) 114Cd(p,n); 116Cd(p,3n); 114Cd(d,2n) therapy, radio-tracer
120gI 1.35 h EC (31.8%); β+ (68.2%) natTe(p,xn) PET
117mSn* 14.00 d IT (100%) 116Cd(α,3n); 116Cd(3He,2n) therapy
121I 2.12 h EC (91.4%); β+ (10.6%) 122Te(p,2n) SPECT
122I*
122Xe/122I*
3.63 min
20.1 h/3.63 min
EC (22%); β+ (78%)
ε (100%)
122Te(d,2n)
127I(p,6n); 127I(d,7n); 124Xe(p,x)
PET analogue of 123,125,131I
123I* 13.2 h EC (100%) 123Te(p,n); 124Te(p,2n); 122Te(d,n);
124Xe(p,x)
Thyroid SPECT diagnostics
124I* 4.2 d EC (78.3%); β+ (22.7%) 123Te(d,n); 124Te(p,n); 124Te(d,2n),
121Sb(α,n)
PET, diagnostic and therapy
127Xe 34.4 d EC (100%) 127I(p,n) SPECT
128Cs
128Ba/128Cs*
3.62 min
2.43 d/3.62 min
EC (31.1%); β+ (68.9%)
ε (100%)
133Cs(p,5n)128Ba PET analogue of 131Cs
Potassium analogue
131Cs*
131Ba/131Cs*
9.689 d
11.50 d/9.689 d
EC (100%)
ε (100%)
131Xe(p,n)
133Cs(p,3n)131Ba → 131Cs
Brachytherapy
145Sm*
145Eu/145Sm*
340 d
5.93 d
ε (100%)
EC (98.099%); β+ (1.91%)
144Sm(d,x)145Sm
natSm(p,x)145Eu →145Sm
Brachytherapy
Therapy
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Table 1 cont.
Radionuclide Half-life Decay mode Reaction (main routes) Application
153Sm* 46.50 h β− (100%) 152Sm(d,p) Therapy
149Pm 53.08 β−: (100%) 148Nd(d,x); 150Nd(d,x);150Nd(p,x) Therapy
140Nd/140Pr* 3.37 d
3.39 min
ε (100%)
EC (49%); β+ (51.0%)
141Pr(p,2n); 141Pr(d,2n); natNd(d,x),
natNd(p,x)
140Pr therapy, 140Nd PET
161Tb* 6.89 d β− (100%) 160Gd(d,n) Therapy
161Ho* 2.48 h ε (100%) 161Dy(p,n)161Ho,162Dy (p,2n); 161Dy(d,2n) Therapy
165Er* 10.36 h ε (100%) 165Ho(p,n); 165Ho(d,2n); natEr(p,x)165Tm
→165Er, natEr(d,x)165Tm→165Er
Therapy
167Tm* 9.25 d ε (100 %) 165Ho(α,2n); 167Er(p,n); 167Er(d,2n);
natYb(p,xn)167Lu167Yb167Tm
Therapy, SPECT
169Yb* 32.018 d ε (100 %) 169Tm(p,n); 169Tm(d,2n);168Er(α,2n) Therapy
177Lu* 6.71 d β− (100%) 176Yb(d,x) Therapy
178Ta*
178W/178Ta*
2.36 h
21.6 d/2.36 h
EC (100%)
ε (100%)
natHf(p,x)178Ta
natTa(p,x)178W; natTa(d,x)178W;
178Hf(α,2n)178W
Therapy (e−, X-ray)
186Re* 3.72 d β− (92.53%), ε (7.47%) 186W(d,2n); 186W(p,n) Therapy
192Ir * 73.829 d β− (95.24%), ε (4.76 %) 192Os(p,n); 192Os(d,2n) Brachytherapy
191Pt* 2.802 d EC (100%) 193Pt(p,3n) Diagnostic for therapy
198Au* 2.6947 d β− (100%) 198Pt(p,n) Brachytherapy
199Au* 3.139 d β− (100%) 198Pt(d,n) Therapy
195Au
195mHg/195mAu*
30.5 s
41 h/30.5 s
IT (100%)
EC (45.8%); IT (54.2%)
197Au(p,3n); natPt(α,x) Angiocardiography
201Tl
201Pb/201Tl*
73.1 h
9.33 h
EC (100%)
EC (99.936%); β+ (0.064%)
203Tl(p,3n)201Pb 201Tl SPECT, myocardia
203Pb 51.9 h ε (100%) natTl(p,x); 205Tl(p,3n) In vivo, in vitro studies
225Ac and 213Bi
229Th−223Ra
decay chain
233U(α)
229Th(α)225Ra(β−)
225Ac(α) 221Fr(α)
217At(α)213Bi(β−)
213Po(α)209Pb(β−)
209Bi(stable)
10.0 d/60.55 min β−(97.8%), a (2.2%) 226Ra(p,2n)225Ac; 232Th(p,x)225Ac α-immunotherapy
α targeted therapy
211At 7.2 h EC (59%), a (41%) 209Bi(α,2n) α targeted therapy
227Th-223Ra de-
cay chain
227Th(α)223Ra(α)
219Rn(α)
215Po(α)
211Pb(β−)
211Bi207Tl(β−)
207Pb(stable)
18.68 d/11.43 d α (100%)
α (100%)
natTh(p,x) α targeted therapy
230U-226Th decay
chain
230U(α)226Th(α)
222Ra(α)218Rn(α)
214Po(α)210Pb(β−)
210Bi(β−)210Po(α)
206Pb(stable)
20.8 d/ 30.57 min α (100%)
α (100%)
231Pa(p,2n)230U α targeted therapy
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